Bone-Rad Therapeutics, founded in Delaware, focuses on revolutionizing the treatment of bone cancers through innovative brachytherapy bone cement. Their core mission is to provide a cost-effective and improved treatment paradigm for tumors in bones. The company offers products such as Spine-Rad™ Cement and the Spine-Cav™ Bone-Cutting Device, targeting the medical market for bone cancer treatments. They also engage in research and publications to advance their technology and treatment methods.
Notable affiliated individuals include experts in oncology and medical device development, though specific names are not provided. Bone-Rad Therapeutics has secured investments from key stakeholders in the medical technology sector. Their achievements include the development and market introduction of Spine-Rad™ Cement, which has significantly impacted the management of bone tumors. The company's innovations have contributed to advancements in brachytherapy, offering new hope for patients with bone cancer.
